Diagnosis and management of pertussis

Tozzi, Alberto E.; Celentano, Lucia Pastore; Atti, Marta Luisa Ciofi degli; Salmaso, Stefania
February 2005
CMAJ: Canadian Medical Association Journal;2/15/2005, Vol. 172 Issue 4, p509
Academic Journal
PERTUSSIS IS INCREASING IN FREQUENCY among children too young to be vaccinated and among adolescents and adults. This increase is due mainly to waning immunity among vaccinated individuals, who become susceptible during adolescence and adulthood and maintain the circulation of Bordetella pertussis. Infants are at highest risk of severe illness requiring hospital admission, complications and death. The clinical presentation in adolescents, adults and vaccinated individuals may be atypical, with paroxysmal cough of short duration or simply a persistent cough. Culture and polymerase chain reaction may be used to identify B. pertussis infection, but their sensitivity is high only in the early phase of the disease. Serologic tests are not standardized for the diagnosis of pertussis, and their clinical application is limited. Erythromycin is still considered in some countries to be the "gold standard" for therapy and prophylaxis; however, azithromycin and clarithromycin seem equally efficacious and are associated with fewer side effects.


Related Articles

  • Protection against pertussis by immunisation. McKendrick, M.W.; Gully, P.R.; Geddes, A.M. // British Medical Journal;11/22/1980, Vol. 281 Issue 6252, p1390 

    Examines the efficacy of pertussis immunization for the protection against Bordetella pertussis infection. Severity of the illness in infants; Epidemiology of pertussis; Protection against the complication of the disease.

  • Neonatal BoÄŸmaca: Vaka Sunumu. Kayiran, Sinan Mahir; Gürakan, Berkan // Journal of the Child / Cocuk Dergisi;Dec2010, Vol. 10 Issue 4, p207 

    Pertussis is a highly contagious respiratory system infection of Bordetella pertussis which can be prevented with an immunization protocol. Although it can be seen in all age groups, the disease pursues a more severe course resulting in hospital stay and mortality in infants under 6 months and...

  • Pertussis vaccination decreased rate of severe infection, illness duration.  // Infectious Disease News;Apr2014, Vol. 27 Issue 4, p55 

    The article discusses a study and an accompanying commentary, published online on March 14, 2014 by "Clinical Infectious Diseases," regarding the lower rate of severe infection and illness duration in children immunized with acellular pertussis vaccine.

  • Manifestations of Pertussis in Immunized Children and Adults. Kirchner, Jeffrey T. // American Family Physician;11/1/1999, Vol. 60 Issue 7, p2148 

    Provides information on the prevalence and incidence of Bordetella pertussis (B. pertussis) infections in adults. Clinical presentation and course of B. pertussis infection among immunized persons; Diagnosis and treatment of B. pertussis infection.

  • Whooping cough vaccine `should be replaced'. Brown, Phyllida // New Scientist;10/23/93, Vol. 140 Issue 1896, p7 

    Reports on the use of acellular vaccines as replacement for whooping cough vaccine or pertussis. Existing whole-cell vaccine based on a suspension of the whole, killed bacterium, Bordetella pertussis; Limitations of the United States Food and Drug Administration-licensed acellular vaccine.

  • Reactions after pertussis vaccine: a manufacturer's experiences and difficulties since 1964. Griffith, A.H. // British Medical Journal;4/1/1978, Vol. 1 Issue 6116, p809 

    Pertussis vaccines vary in quality, safety, and efficacy according to the production strains of Bordetella pertussis, the method of manufacture, and quality control procedures. It is therefore not justifiable to combine information on the incidence, nature, and severity of reactions after all...

  • Editorial Commentary: Accounting for Pertussis. DeMaria, Alfred // Clinical Infectious Diseases;Jun2012, Vol. 54 Issue 12, p1736 

    An introduction is presented in which the editor discusses the article on pertussis vaccines.

  • Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children. Vickers, David; Ross, Allen G.; Mainar-Jaime, Raúl C.; Neudorf, Cordell; Shah, Syed // CMAJ: Canadian Medical Association Journal;11/7/2006, Vol. 175 Issue 10, p1213 

    Background: The transition from a whole-cell to a 5-component acellular pertussis vaccine provided a unique opportunity to compare the effect that each type of vaccine had on the incidence of pertussis, under routine conditions, among children less than 10 years of age. Methods: Analyses were...

  • Time since last vaccine dose in PCR-positive and PCR-negative children with suspected pertussis to monitor pertussis vaccine effectiveness. Riffelmann, M.; Mohr, J.; Hellenbrand, W.; Wirsing von Koenig, C. // European Journal of Clinical Microbiology & Infectious Diseases;May2014, Vol. 33 Issue 5, p805 

    We evaluated whether the results of diagnostic polymerase chain reaction (PCR) testing combined with time since last vaccine dose could be used to monitor the effectiveness of acellular pertussis vaccines. In 258 consecutive nasopharyngeal swabs from children and adolescents with typical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics